Treatment progress of pediatric steroid-resistant nephrotic syndrome
10.3760/cma.j.cn101070-20210716-00834
- VernacularTitle:儿童激素耐药型肾病综合征治疗进展
- Author:
Haiping YANG
1
;
Huan CHI
;
Qiu LI
Author Information
1. 重庆医科大学附属儿童医院肾内科，国家儿童健康与疾病临床医学研究中心，儿童发育疾病研究教育部重点实验室，儿科学重庆市重点实验室，重庆 400014
- Keywords:
Steroid-resistant nephrotic syndrome;
Immunosuppressive agents;
Treatment;
Progress;
Child
- From:
Chinese Journal of Applied Clinical Pediatrics
2021;36(17):1290-1295
- CountryChina
- Language:Chinese
-
Abstract:
Primary nephrotic syndrome (PNS) is one of the most common glomerular diseases in children.Steroid-resistant nephrotic syndrome (SRNS) is defined as no remission of nephrotic syndrome after daily Prednisone treatment at an adequate oral dose for 4 weeks, which is classified as idiopathic SRNS and inherited SRNS according to the presence or absence of monogenic disorder.At present, steroid combined with calcineurin inhibitor (CNI) is preferred to idiopathic SRNS, and 50%-70% of children can achieve complete or partial remission.A small proportion of children with idiopathic SRNS and the majority of inherited SRNS may be resistant to different immunosuppressive agents with two different mechanisms, including CNI.They, unfortunately, gradually progress to end-stage renal disease within 5-10 years.In this paper, the therapeutic advances and future prospects in pediatric SRNS are reviewed.
